Biotechnology company AMR Bio has submitted written comments in efforts to shape the US National Action Plan to combat antibiotic-resistant bacteria. 

AMR Bio wrote to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) ahead of the council’s 27th public meeting on 16 June 2026, contributing to the next iteration of the US National Action Plan. 

The revival of PACCARB, which had been inactive since early 2025 and provides advice and recommendations to the Secretary of State & Human Services (HHS) in the US, signals renewed political commitment in the US to tackle antibiotic resistance. 

The plan aims to bring together industry, regulators and policymakers to address the growing challenge of antibiotic resistance and accelerate access to new preventative and therapeutic solutions. 

AMR Bio’s submission, made by Executive Chair Nigel Brooksby, sets out a series of recommendations for the plan’s next iteration, including calls for infection prevention to be prioritised as a core AMR strategy and elevated to the same strategic level as antibiotic development.  

The submission also calls for federal policy to expand its support beyond traditional systemic antibiotics to include topical antimicrobials and other novel preventive technologies, and for new incentive frameworks that reward prevention-based innovation alongside treatment. 

“The revival of PACCARB is a welcome and important development, and we are pleased to have contributed AMR Bio’s perspective at this pivotal stage of the National Action Plan,” Brooksby said. 

“The United States has a critical role to play in driving global progress against antimicrobial resistance, and policymakers have an opportunity to create an environment that supports the development and adoption of innovative new approaches.   

“We look forward to attending the virtual meeting on 16 June and continuing our engagement with US stakeholders as we advance the XF-73 programme.”